Prevalence and survival prognosis of prostate cancer in patients with end-stage renal disease: a retrospective study based on the Korea national database (2003-2010)

Kim, Sung-Han; Joung, Jae Young; Suh, Yoon Seok; Kim, Young Ae; Hong, Jin Hyuk; Kuark, Tong Sun; Lee, Eun Sook; Lee, Kang Hyun

doi:10.18632/oncotarget.19453

Cited by 6 publications

(6 citation statements)

References 29 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many countries have analyzed various diseases in the field of urology using national insurance data [ 3 4 5 ]. Several multicenter studies on urological diseases have been conducted in Korea, but national survey or population-based studies are lacking.…”

Section: Introductionmentioning

confidence: 99%

Study on the prevalence and incidence of urolithiasis in Korea over the last 10 years: An analysis of National Health Insurance Data

2018

View full text Add to dashboard Cite

PurposeWe aimed to analyze the incidence and prevalence of urolithiasis in Korea over the last decade using the National Health Insurance (NHI) sample cohort data.Materials and MethodsFrom January 2002 to December 2013, we enrolled sample cohort data from the NHI. Patients diagnosed with international classification of diseases code N20 or N13.2 were included. The incidence and prevalence rate was counted from the same period and patients previously diagnosed with urolithiasis were excluded. We compared the incidence and prevalence of urolithiasis by region, age, and sex, and identified the changes.ResultsTotal 1,111,828 subjects were included. Of these subjects, 36,857 had urolithiasis. The male-to-female ratio was 1.57:1, and total incidence rate was 3.27 per 1,000 person-years (1,000p-yrs). The annual incidence was lowest in 2013 (3,138 patients) and highest in 2005 (3,751 patients). Incidence rate by diagnostic code was highest in ureter stone only (2.49 per 1,000p-yrs) and was lowest in kidney and ureter stone both (0.17 per 1,000p-yrs). Prevalence gradually increased from 3,172 in 2002 and 5,758 in 2013. Jeollanam-do had the highest incidence rate of 3.70 persons per 1,000p-yrs, and Jeju had the lowest rate of 2.84 persons per 1,000p-yrs. In gender analysis, Daegu had the highest incidence (4.56) in males, Jeollanam-do had the highest incidence (3.20) in females.ConclusionsAnnual incidence remained stable, whereas prevalence gradually increased. The incidence in male was 1.57 times higher than female, and the peak incidence age was 45–49 years, with the highest incidence occurring in Jeollanam-do and the lowest in Jeju.

show abstract

Section: Introductionmentioning

confidence: 99%

Study on the prevalence and incidence of urolithiasis in Korea over the last 10 years: An analysis of National Health Insurance Data

2018

View full text Add to dashboard Cite

show abstract

“…28,29 Therefore, a large number of patients with high risk and advanced disease were enrolled in study. However, this patient distribution differs from that in contemporary series of renal transplant candidates, of whom 91% with newly diagnosed prostate cancer are in the low risk group 8 and overall survival is mainly predicted by kidney function status. Median survival in patients on hemodialysis is less than 10 years and probably less than 5 years in the presence of associated morbidities (ie diabetes and heart failure).…”

Section: Immunosuppression In Renal Transplantmentioning

confidence: 60%

“…Kim et al evaluated the pattern and prognosis of prostate cancer in 3,945 patients with ESRD. 8 Most of these patients were at low risk, including 91% with cT1c, Gleason grade 6 and pT2 after RP, with 100% recurrence-free survival. Kim et al found that in these patients it was mainly kidney function status rather than prostate cancer which determined survival.…”

Section: Immunosuppression In Renal Transplantmentioning

confidence: 93%

Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer

et al. 2019

View full text Add to dashboard Cite

Purpose: Current trends in renal transplantation, such as improved allograft/ recipient survival and expanded organ transplantation eligibility criteria in older recipients, are concomitant with increasingly detected low risk prostate cancer in candidates for or recipients of renal transplantation. We reviewed the evidence regarding prostate cancer screening, diagnosis and management in renal transplant candidates and recipients. We focused on published reports of prostate cancer incidence and diagnosis in patients with end stage renal disease, pretransplant screening recommendations, and recommendations regarding waiting time between treatment and active wait listing after the prostate cancer diagnosis in renal transplant candidates. In addition, we examined the natural history of prostate cancer development after renal transplantation in the setting of standard immunosuppression. Materials and Methods: We reviewed the English language literature using search terms including prostate cancer, end stage renal disease, renal transplantation, prostate cancer screening, prostate specific antigen, prostate cancer treatment and active surveillance in various combinations. Results: Prostate cancer screening is still widely done in almost all patients with end stage renal disease before and after transplantation. Active treatment of any patients with prostate cancer and a 5-year waiting period before transplantation can negatively affect the collective pool of participants and the overall survival of patients on dialysis. Several groups have proposed a shorter waiting time to kidney transplantation in patients with low risk prostate cancer. Conclusions: There are no standardized guidelines for screening and management of prostate cancer before and after transplantation. In the era of low risk prostate cancer end stage renal disease is a significant competing mortality risk factor. The role of active surveillance in these complex cases has yet to be well investigated. Further studies and nomograms are urged to integrate risk stratified screening and treatment protocols before and after renal transplantation.

show abstract

“…Previous studies have shown that localized PCa is the most common presentation of PCa in dialysis patients. 14 , 15 Since localized PCa is asymptomatic, it is likely that the majority of the cases, especially those in the low‐risk group, were diagnosed during screening. Despite the controversy around screening with PSA even in the general population, dialysis patients who are getting evaluated for a KT undergo screening with PSA at a very high rate of 89% during their evaluation.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Treatment patterns and survival of low and intermediate‐risk prostate cancer in end‐stage kidney disease: A retrospective population cohort study

et al. 2023

View full text Add to dashboard Cite

Background:In accordance with guidelines, observation with or without active surveillance for low-risk prostate cancer increased in recent years in the general population. We compared treatment patterns and mortality for low-and intermediate-risk prostate cancer and mortality rates among end-stage kidney disease (ESKD) and non-ESKD patients.Methods: This is a retrospective population-based observational cohort study of Surveillance, Epidemiology, and End Results-Medicare data of men aged 66 years and older with localized prostate cancer (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). ESKD status was determined using Medicare billing codes. Multivariable logistic regression models and Cox-proportional hazards models were used to study definitive treatment patterns and mortality, respectively.Results: For low-risk prostate cancer, dialysis patients (N = 83) had lower but not statistically significant odds (OR, 0.74; 95% CI: 0.48-1.16) of receiving definitive treatment than non-ESKD patients (N = 24,935). For those with intermediate-risk prostate cancer, dialysis patients (N = 254) had lower odds to receive definitive treatment (OR, 0.54; 95% CI: 0.42-0.72) than non-ESKD patients (N = 60,883). From 2004-2010 to 2011-2015, for patients with low-risk prostate cancer, while the receipt of definitive treatment for non-ESKD patients trended down from 72% to 48%, it trended up for dialysis patients from 55% to 65%. Kidney transplant patients (N = 33 for low-risk and N = 91 for intermediate-risk) had lower rates of definitive treatment for low-risk and similar rates of treatment for intermediaterisk prostate cancer compared to non-ESKD patients. Conclusions:The disparity in definitive treatment rates for low-risk prostate cancer among dialysis patients exists despite their high mortality, compared to the general population. Received definitive treatment 48 (57.8) 16 (48.5) 16,174 (64.9) 0.059 176 (69.3) 73 (80.2) 49,029 (80.5) <0.01 Abbreviations: ESKD, end-stage kidney disease; SEER, surveillance, epidemiology, and end results; SD, standard deviation. a Age is expressed as mean and standard deviation. Other variables are percentages. b Low risk: T stages T1c and T2a, Gleason score of 6 or less, and serum PSA level of ≤10 ng/mL and intermediate risk: T stages T2b and T2c, Gleason score of 7, and serum PSA level of 10-20 ng/mL. c Analysis of Variance for Age differences and chi-square test for all the other variables. d Cardiovascular disease includes history of acute myocardial infarction, stroke, congestive heart failure, ischemic heart disease, or atrial fib.

show abstract

Prevalence and survival prognosis of prostate cancer in patients with end-stage renal disease: a retrospective study based on the Korea national database (2003-2010)

Cited by 6 publications

References 29 publications

Study on the prevalence and incidence of urolithiasis in Korea over the last 10 years: An analysis of National Health Insurance Data

Study on the prevalence and incidence of urolithiasis in Korea over the last 10 years: An analysis of National Health Insurance Data

Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer

Treatment patterns and survival of low and intermediate‐risk prostate cancer in end‐stage kidney disease: A retrospective population cohort study

Contact Info

Product

Resources

About